<![CDATA[Long-Term Efficacy Data on Zanubrutinib from SEQUOIA]]>

Data ReadoutpositiveZanubrutinibAcalabrutinibPositive

AI Analysis

Summary

Long-term efficacy data on zanubrutinib from the SEQUOIA trial is being reviewed. The ELEVATE-TN trial demonstrated acalabrutinib's superiority over chlorambucil-obinutuzumab in frontline chronic lymphocytic leukemia.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

ELEVATE-TN trial demonstrated acalabrutinib superiority over chlorambucil-obinutuzumab in frontline CLL

Importance:6/10

Sentiment:

0.70

oncologyCLLBruton tyrosine kinase inhibitorclinical efficacyfrontline treatment

Read the original article

Published by Cancer Network on July 14, 2026 12:00 PM

Read Original